Towards in Vitro Models for Reducing or Replacing the Use of Animals in Drug Testing

Avila A, Bebenek I, Mendrick D, Peretz J, Yao J, Brown P . Gaps and challenges in nonclinical assessments of pharmaceuticals: An FDA/CDER perspective on considerations for development of new approach methodologies. Regul Toxicol Pharmacol. 2023; 139:105345. DOI: 10.1016/j.yrtph.2023.105345. View

Avila A, Bebenek I, Bonzo J, Bourcier T, Davis Bruno K, Carlson D . An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs). Regul Toxicol Pharmacol. 2020; 114:104662. DOI: 10.1016/j.yrtph.2020.104662. View

Valentin J, Leishman D . 2000-2023 over two decades of ICH S7A: has the time come for a revamp?. Regul Toxicol Pharmacol. 2023; 139:105368. DOI: 10.1016/j.yrtph.2023.105368. View

Schmeisser S, Miccoli A, von Bergen M, Berggren E, Braeuning A, Busch W . New approach methodologies in human regulatory toxicology - Not if, but how and when!. Environ Int. 2023; 178:108082. PMC: 10858683. DOI: 10.1016/j.envint.2023.108082. View

Parish S, Aschner M, Casey W, Corvaro M, Embry M, Fitzpatrick S . An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regul Toxicol Pharmacol. 2020; 112:104592. DOI: 10.1016/j.yrtph.2020.104592. View

Fabre K, Berridge B, Proctor W, Ralston S, Will Y, Baran S . Introduction to a manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. Lab Chip. 2020; 20(6):1049-1057. DOI: 10.1039/c9lc01168d. View

Vogt N . Assembloids. Nat Methods. 2021; 18(1):27. DOI: 10.1038/s41592-020-01026-x. View

Ingber D . Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022; 23(8):467-491. PMC: 8951665. DOI: 10.1038/s41576-022-00466-9. View

Low L, Mummery C, Berridge B, Austin C, Tagle D . Organs-on-chips: into the next decade. Nat Rev Drug Discov. 2020; 20(5):345-361. DOI: 10.1038/s41573-020-0079-3. View

10.

Clapp N, Amour A, Rowan W, Candarlioglu P . Organ-on-chip applications in drug discovery: an end user perspective. Biochem Soc Trans. 2021; 49(4):1881-1890. PMC: 8421049. DOI: 10.1042/BST20210840. View

11.

Baran S, Brown P, Baudy A, Fitzpatrick S, Frantz C, Fullerton A . Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate). ALTEX. 2022; 39(2):297–314. DOI: 10.14573/altex.2112203. View

12.

Kopec A, Yokokawa R, Khan N, Horii I, Finley J, Bono C . Microphysiological systems in early stage drug development: Perspectives on current applications and future impact. J Toxicol Sci. 2021; 46(3):99-114. DOI: 10.2131/jts.46.99. View

13.

Cairns E, Benson M, Bedoya-Perez M, Macphail S, Mohan A, Cohen R . Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing. Front Pharmacol. 2023; 14:1142680. PMC: 10279775. DOI: 10.3389/fphar.2023.1142680. View

14.

Marx U, Akabane T, Andersson T, Baker E, Beilmann M, Beken S . Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 2020; 37(3):365-394. PMC: 7863570. DOI: 10.14573/altex.2001241. View

15.

Vulto P, Joore J . Adoption of organ-on-chip platforms by the pharmaceutical industry. Nat Rev Drug Discov. 2021; 20(12):961-962. DOI: 10.1038/s41573-021-00323-0. View

16.

Ewart L, Apostolou A, Briggs S, Carman C, Chaff J, Heng A . Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Commun Med (Lond). 2022; 2(1):154. PMC: 9727064. DOI: 10.1038/s43856-022-00209-1. View

17.

Proctor W, Foster A, Vogt J, Summers C, Middleton B, Pilling M . Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol. 2017; 91(8):2849-2863. PMC: 5515971. DOI: 10.1007/s00204-017-2002-1. View

18.

Schaller T, Snyder D, Spasojevic I, Gedeon P, Sanchez-Perez L, Sampson J . First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach. J Immunother Cancer. 2020; 8(1). PMC: 7254109. DOI: 10.1136/jitc-2019-000213. View

19.

Ji Y, Knee D, Chen X, Dang A, Mataraza J, Wolf B . Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose. Clin Transl Sci. 2022; 15(9):2218-2229. PMC: 9468570. DOI: 10.1111/cts.13355. View

20.

Dudal S, Hinton H, Giusti A, Bacac M, Muller M, Fauti T . Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB. J Immunother. 2016; 39(7):279-89. DOI: 10.1097/CJI.0000000000000132. View